Literature DB >> 16918824

A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed.

M Norberg1, J W Eriksson, B Lindahl, C Andersson, O Rolandsson, H Stenlund, L Weinehall.   

Abstract

OBJECTIVE: To identify a screening model that predicts high risk of future type 2 diabetes and is useful in clinical practice. DESIGN AND METHODS: Incident case-referent study nested within a population-based health survey. We compared screening models with three risk criteria and calculated sensitivity, specificity, positive (PPV) and negative (NPV) predictive values and attributable proportion. We used fasting plasma glucose (FPG) alone or with an oral glucose tolerance test (OGTT), glycosylated haemoglobin A (HbA1c) (normal range 3.6-5.3%), body mass index (BMI), triglycerides and family history of diabetes (FHD).
SETTING: Participants in a health survey at all primary care centres (n=33,336) and subjects with diagnosed type 2 diabetes in primary and hospital care (n=6088) in Umeå during 1989-2001.
SUBJECTS: Each of the 164 subjects who developed clinically diagnosed type 2 diabetes (median time to diagnosis of 5.4 years) and 304 sex- and age-matched referents without diabetes diagnosis.
RESULTS: Screening models with at least one criterion present had sensitivities of 0.90-0.96, specificities of 0.43-0.57 and PPVs of 8-9%. Combinations of the criteria, FPG>or=6.1 mmol L-1 (capillary plasma), HbA1c>or=4.7% and BMI>or=27 in men and BMI>or=30 in women, had sensitivities, specificities and PPVs of 0.66%, 0.93% and 32%, and 0.52%, 0.97% and 46% respectively. Using FHD as one of three risk criteria showed comparable results. Addition of triglycerides or OGTT did not improve the prediction.
CONCLUSIONS: The combination of HbA1c, FPG and BMI are effective in screening for individuals at risk of future clinical diagnosis of type 2 diabetes. OGTT or FHD is not necessary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918824     DOI: 10.1111/j.1365-2796.2006.01689.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  25 in total

1.  Advanced glycation end products of DNA: quantification of N2-(1-Carboxyethyl)-2'-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry.

Authors:  Timothy Synold; Bixin Xi; Gerald E Wuenschell; Daniel Tamae; James L Figarola; Samuel Rahbar; John Termini
Journal:  Chem Res Toxicol       Date:  2008-11       Impact factor: 3.739

Review 2.  Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?

Authors:  N Sattar; S G Wannamethee; N G Forouhi
Journal:  Diabetologia       Date:  2008-04-08       Impact factor: 10.122

3.  An Integrative, Multilevel, and Transdisciplinary Research Approach to Challenges of Work, Family, and Health.

Authors:  Jeremy W Bray; Erin L Kelly; Leslie B Hammer; David M Almeida; James W Dearing; Rosalind B King; Orfeu M Buxton
Journal:  Methods Rep RTI Press       Date:  2013-03

4.  Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes.

Authors:  Madhumita Jagannathan-Bogdan; Marie E McDonnell; Hyunjin Shin; Qasim Rehman; Hatice Hasturk; Caroline M Apovian; Barbara S Nikolajczyk
Journal:  J Immunol       Date:  2010-12-17       Impact factor: 5.422

5.  The relative importance of modifiable potential risk factors of type 2 diabetes: a meta-analysis of two cohorts.

Authors:  Maarit A Laaksonen; Paul Knekt; Harri Rissanen; Tommi Härkänen; Esa Virtala; Jukka Marniemi; Arpo Aromaa; Markku Heliövaara; Antti Reunanen
Journal:  Eur J Epidemiol       Date:  2009-12-13       Impact factor: 8.082

6.  The Västerbotten Intervention Programme: background, design and implications.

Authors:  Margareta Norberg; Stig Wall; Kurt Boman; Lars Weinehall
Journal:  Glob Health Action       Date:  2010-03-22       Impact factor: 2.640

Review 7.  A1C level and future risk of diabetes: a systematic review.

Authors:  Xuanping Zhang; Edward W Gregg; David F Williamson; Lawrence E Barker; William Thomas; Kai McKeever Bullard; Giuseppina Imperatore; Desmond E Williams; Ann L Albright
Journal:  Diabetes Care       Date:  2010-07       Impact factor: 19.112

Review 8.  Type 2 Diabetes Prevention: Implications of Hemoglobin A1c Genetics.

Authors:  Aaron Leong; James B Meigs
Journal:  Rev Diabet Stud       Date:  2016-02-10

9.  Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon Hospital Health Management Center Study 6 (TOPICS 6).

Authors:  Y Heianza; Y Arase; S D Hsieh; K Saito; H Tsuji; S Kodama; S Tanaka; Y Ohashi; H Shimano; N Yamada; S Hara; H Sone
Journal:  Diabetologia       Date:  2012-09-07       Impact factor: 10.122

10.  Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Authors:  David Preiss; Sofia Zetterstrand; John J V McMurray; Jan Ostergren; Eric L Michelson; Christopher B Granger; Salim Yusuf; Karl Swedberg; Marc A Pfeffer; Hertzel C Gerstein; Naveed Sattar
Journal:  Diabetes Care       Date:  2009-02-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.